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CASE PRESENTATION
A 54-year-old Caucasian man wished to donate a kidney
to his adult daughter, who reportedly had end-stage renal
disease secondary to a glomerulonephritis of unknown
origin inherited through her mother, thus ruling out any
potential donors from the maternal side. As the donor and
recipient transplant teams were located in separate
centers, all information pertaining to the recipient was
collected from the potential kidney donor himself. As a
child, his daughter had received a deceased donor renal
transplant, which failed for unknown reasons after 3.5
years. He was previously turned down as a donor 7 years
before presentation for unknown reasons. His past
medical history was significant for hyperlipidemia
controlled with a statin, hypothyroidism treated with
L-thyroxine, and removal of three colonic polyps 12 years
before presentation. Surgical history was significant for
cholecystectomy and laser-assisted in situ keratomileusis
surgery. He was a nonsmoker and ingested two alcoholic
drinks per day. His mother had type 2 diabetes mellitus
(T2DM) and died of congestive heart failure in her
eighties. On examination, body mass index was 30kg/m2
and blood pressure was 126/85. The remainder of the
examination was within normal limits. Laboratory values,
shown in Table 1, were consistent with the diagnosis of
impaired fasting glucose (IFG). Repeat testing showed
persistence of the IFG. On the basis of this diagnosis alone,
his risk of future T2DM was estimated at approximately
25% in the next 3–5 years.1 Additional diabetes risk factors
included the following: obese with abdominal obesity;
type 2 diabetes in first-degree relative; sedentary lifestyle.
Although they technically did not meet the American
Diabetes Association criteria for diabetes risk factors, the
following were also highly suggestive of increased
diabetes risk: hypertriglyceridemia, elevated diastolic
blood pressure.
Using the American Diabetes Association Diabetes
Personal Health Decisions calculator2 to incorporate the
potential donor’s personal and family history, his 10- and
30-year risk of developing T2DM were estimated at 75 and
81%, respectively.
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Despite his increased risk of developing T2DM, the potential
donor stated that he ‘understood the risks, but felt that his
potential ability to help his daughter far outweighed this’ and
that ‘there was no one else available to donate.’ He was
‘willing to do anything’ to ensure that he was able to proceed
with donation. Owing to the lack of data regarding long-term
risks in recommending living kidney donation in the donor
with ‘prediabetes’, the transplant team expressed concern that
proceeding with donation may not be in the donor’s best
health interests. However, there was an appreciation that the
willingness of a parent to bear a greater risk to help his/her
child cannot, and should not, be undervalued. As such, a
consult was obtained from the medical bioethics service to
determine the ethics of allowing this man to proceed with
living kidney donation. As part of the assessment, the
potential donor first explained to the ethics team his
incontrovertible wish to donate a kidney to his daughter.
He stated that he was fully aware that he was at risk of
developing T2DM and thus potentially diabetic kidney
disease, progression of which may be exacerbated by having
a single kidney. He outlined his willingness to modify his
lifestyle to decrease this risk, as he felt the importance of
donating to his daughter far outweighed any risk to himself.
He emphasized that he had made repeated visits to the clinic
at the request of the transplant team to discuss the issue of
prediabetes in great detail, and felt that he was in an excellent
position to give informed consent with regard to the issue of
donation. The transplant team then outlined the limited
evidence and uncertainty surrounding proceeding with
donation in a donor with IFG. The ethics team cited the
principles of autonomy, beneficence, and maleficence in
assessing this case and in their opinion ‘yjust as the patient’s
autonomous judgment must be respected, so too must the
educated judgment of the renal team be respected.’ It was
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decided that to recommend donation was ethically defen-
sible. However, as stated at the Amsterdam Forum on the
Care of the Live Kidney Donor,3 obesity should be considered
a potential risk factor for renal disease, though long-term
data on outcomes of obese donors are lacking.4 Thus, on the
advice of the transplant team and in accordance with the
current guidelines,3 the patient lost 13.6 kg (30lbs) before
donation, decreasing his 10-year risk of T2DM from 75 to
20%.2 The patient then successfully donated his kidney.
‘MEDICALLY COMPLEX’ LIVING DONORS
The global epidemic of end-stage renal disease has resulted in
a widening gap between the supply and demand of kidney
transplants.5,6 The ever-increasing waiting times for
deceased-donor kidneys have focused attention on living
donation as a useful way to increase the supply of organs for
transplant candidates.7 However, as both living and deceased
donor transplant kidneys are in short supply, many renal
transplant centers are faced with evaluating potential living
donors with risk factors for developing future kidney disease,
a group of patients termed ‘medically complex living
donors’,8 a group which includes donors with prediabetes.
Living kidney donation is performed with the expectation
that the risk for short- and long-term harm to the donor is
minimal, although it is important to note that most
published series have only included low-risk donors. In the
case of the medically complex living donor, however,
insufficient data about long-term outcomes and lack of
consensus regarding important risk factors8–10 force trans-
plant professionals to tailor their decisions regarding
suitability for kidney donation to the particular circum-
stances of each donor.11
Although living donor kidney transplantation yields
the best results in terms of recipient and graft survival
compared with other renal replacement therapies,6 there are
some risks to the donor that may be directly attributable to
nephrectomy. Ever since the recognition of hyperfiltration
injury in animals undergoing renal ablation,12,13 there has
been concern over the renal consequences of living kidney
donation.11,14–16 However, the majority of studies on live
donors have not found increased risk of end-stage renal
disease or mortality.17–25 Several long-term follow-up studies
in humans have suggested that hyperfiltration of the
remaining kidney after unilateral donor nephrectomy was
not associated with increased risks of adverse effects for
more than 10 years,15,18,23,24,26,27 although other studies have
suggested that the risk of kidney disease is elevated in
living renal donors.24,26,28–30 A recent meta-analysis suggests
that a 5 mm Hg increase in blood pressure occurs within
5–10 years after donation above that anticipated with
normal aging,31 and a second meta-analysis reported a
slightly increased risk of proteinuria but no increase in
loss of kidney function in living kidney donors,32 although
these results could reflect—at least in part—surveillance bias.
Most people do well with a single kidney and in fact, donors
may even live longer than nondonors, although this
observation may simply indicate the careful selection of
living donors from among very healthy candidates.33 Of
importance, however, is that these studies have not
consistently distinguished between ‘medically complex’ and
‘non-medically complex’ living donors, and extrapolation of
these results to the case described in our report, a donor
with prediabetes, may not be appropriate. Conversely, it is
equally important to note that historically the oral glucose
tolerance test was not performed as part of the donor work-
up, suggesting that some older studies on long-term
outcomes of kidney donors may have included donors
today who would be defined as ‘prediabetic.’ Although
the individual described in this report showed more than one
clinical characteristic that may increase his risk of medical
sequelae, we have chosen to focus our discussion on the
literature surrounding prediabetes. Prediabetes is a common
condition, and it is estimated that more than 54 million
American adults are affected with IFG.34 Although debate
continues over the benefits and harms of screening and then
treating adults who have asymptomatic diabetes or pre-
diabetes,34 prediabetes is a significant risk factor for the
development of type 2 diabetes, microvascular, and macro-
vascular disease.35 How best to evaluate and consider the
future risk of developing diabetes in live kidney donors is not
well defined and varies considerably between programs.36
Table 1 | Laboratory values
Value (reference range)
Serum/blood
Creatinine 1.09mg/dl (0.7–1.3)
(97mmol/l (62–115))
Urea nitrogen 6mg/dl (9–25)
(2.2mmol/l (3.2–8.9))
Fasting total cholesterol 157.6mg/dl (o200–239)
(4.04mmol/l (o5.1–6.1))
Fasting triglycerides 231mg/dl (150–499)
(2.6mmol/l (1.7–5.6))
Fasting high-density lipoprotein 46.8mg/dl (40–60)
(1.2mmol/l (1.0–1.5))
Fasting low-density lipoprotein 62.4mg/dl (o100–189)
(1.6mmol/l (o2.6–4.6))
Prostate-specific antigen 0.5 ng/ml (0–4 ng/ml)
HIV Negative (negative)
Hepatitis B surface antigen Negative (negative)
Hepatitis C antibody Negative (negative)
Fasting glucose 120.9mg per 100ml (54–118)
(6.7mmol/l (3.0–6.0))
2 h glucose on 75g OGTT 79mg per 100ml
(o110) (4.4mmol/l (o6.1))
Glomerular filtration rate
(99mTc-diethylenetriamine–
pentaacetic acid clearance)
99ml/min/1.73m2 (490)
Urine
24 h protein 121mg, repeat 94mg
(30–150/24 h)
Creatinine clearance 66ml/min, repeat 62ml/min (58–120)
OGTT, oral glucose tolerance test.
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PREDIABETES AND THE KIDNEY
Although diabetes mellitus has been clearly established as a
major risk factor for the development of kidney disease and is
the leading cause of end-stage renal disease in North
America6 and other developed countries, there are few
studies examining the effects of prediabetes on the kidney.
The term ‘prediabetes’ is applied in the setting of impaired
glucose tolerance (IGT) or IFG and indicates a relatively high
probability for the development of diabetes, microvascular,
and macrovascular disease.1,35,37 The natural history of both
IFG and IGT is variable, withB25% progressing to diabetes,
50% remaining in their abnormal glycemic state, and 25%
reverting to normal glucose tolerance over an observational
period of 3–5 years.38–40 However, with longer observation,
the majority of individuals with IFG appear to develop
T2DM.1 Glomerular hyperfiltration, the hallmark of the
onset of diabetic nephropathy,41 is positively correlated to
fasting plasma glucose 42 and has been observed in renal
physiological studies in individuals with IGT,43,44 which
suggests that the increased renal risk associated with diabetes
may also occur in the prediabetic stage. Although no
association was found between hyperinsulinemia or IGT
and microalbuminuria in a nondiabetic Caucasian popula-
tion,45 studies in other populations have reported an
association between insulin resistance and an increased risk
of microalbuminuria in the absence of diabetes.46,47 A large
cross-sectional study identified a significant dose–response
relationship among insulin resistance, insulin level, and risk
of chronic kidney disease among nondiabetic participants,48
and impaired insulin sensitivity may be involved in the
development of renal dysfunction at an early stage, before the
onset of diabetes or prediabetic glucose elevations.49
Although this study was not designed to determine causality,
worsening glycemic status has been associated with an
increased risk of new renal dysfunction, with IFG or IGT
conferring a 65% increased odds of developing chronic
kidney disease over a 7-year period compared with
normoglycemic individuals.50
Worsening of insulin resistance has been found to be a risk
factor for renal injury because of greater glomerular capillary
and systemic blood pressures in older subjects.51 In healthy
humans, higher insulin levels were associated with increased
activity of the intrarenal renin–angiotensin system,52 activa-
tion of which has been implicated in the pathophysiology of
diabetic nephropathy. In a study of patients undergoing renal
biopsy for proteinuria, isolated diffuse thickening of the
glomerular basement membrane was proposed as a renal
lesion associated with prediabetes,53 although a firm relation-
ship between this histological finding and the development of
diabetes remains to be proven.
Donor nephrectomy in the case of normal renal function
results in functional adaptation, hypertrophy, and hyperfil-
tration of the remaining kidney.54,55 While the first stage of
diabetic, and perhaps prediabetic, nephropathy is glomerular
hyperfiltration,41 the increase in glomerular filtration rate in
uninephrectomized nondiabetic individuals is due to the
increase in renal plasma flow,54 whereas in diabetic patients,
the increase of renal plasma flow accounts for approximately
40% of the increase in glomerular filtration rate.56 Therefore,
the mechanisms of hyperfiltration of nondiabetic single-
kidney patients are probably not the same as those of diabetic
patients. Although the effects of prediabetes in the setting of a
single kidney are not known, a cross-sectional study
concluded that glomerular hyperfiltration related to single-
kidney status conferred an increased risk of developing renal
disease in the presence of diabetes,57 though few subjects in
this study were live kidney donors. However, no definite link
between ‘prediabetes’ and the risk of kidney dysfunction has
been shown, suggesting that the absolute risk of developing a
glycemia-related kidney abnormality in the donor described
in this report was probably not high.
CURRENT GUIDELINES FOR LIVING KIDNEY DONATION
The person who gives consent to be a live organ donor
should be competent, willing to donate, free from coercion,
medically and psychosocially suitable, fully informed of the
risks and benefits as a donor, and fully informed of the risks,
benefits, and alternative treatment available to the recipient.
The benefits to both donor and recipient must outweigh the
risks associated with the donation and transplantation of the
living donor organ.58 The Amsterdam Forum has set forth a
comprehensive list of medical criteria that is now used
internationally in the evaluation of potential kidney donors;3
although a diagnosis of diabetes precludes donation, the
presence of prediabetes does not necessarily render a
potential donor unacceptable. It should be noted, however,
that the purpose of the guidelines is not to replace the
individual physician’s medical judgment in deciding to accept
(or not) a potential live kidney donor. A recently published
report on evaluation of the potential living kidney donor
suggests that prediabetes is a relative contraindication to
donation, and prospective donors with IFG or IGT should be
assessed on an individual basis.59
FOLLOW-UP OF CASE PRESENTATION
The donor did not comply with scheduled follow-up at our
clinic, opting instead to follow up with his primary care
physician. As such, we are not aware of any further outcomes
other than a creatinine of 1.4 mg/dl (124 mmol/l) 6 months
post-donation. Similarly, we are unaware of the recipient’s
current status.
CLINICAL PERSPECTIVE AND CONCLUSIONS
Nephrologists assessing potential candidates for living
donation should take into consideration the diagnosis of
‘prediabetes’. The role of the nephrologist assessing a person
willing to donate a kidney is to be the advocate of the
potential donor, and recommend proceeding with donation
if, and only if, the degree of risk with the procedure is
acceptable to both the physician and the patient. Although
the ethical complexities of living kidney donation are beyond
the scope of this article, a thorough discussion between the
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two parties of both the short- and long-term potential risks
associated with the procedure based on the currently
available evidence is of clear importance, as ‘uncertainty is
not a stumbling block to informed consent’60 if the
uncertainty is communicated to the potential donor. In fact,
potential donors are more likely than potential recipients and
transplant professionals to consider donation acceptable,
even when long-term donor risks are uncertain.61 As the
population at risk for diabetes and the ‘need’ for kidneys each
continues to increase, the scenario described in this report is
more likely to become increasingly common. As sparse data
about long-term risk of uninephrectomy in the donor with
prediabetes exist, current guidelines suggest that proceeding
with kidney donation in the patient with prediabetes is
acceptable, provided the potential donor is aware of the
potential risks and is thus able to make an informed decision.
Nonetheless, prediabetic donors should likely be counseled to
engage in activities that reduce their future risk of diabetes
(increase physical activity, weight loss, and metformin
treatment in some individuals),1 given the clear association
between diabetes and nephropathy.6
It was unclear to the transplant team if the potential
recipient (who was at a different center) was aware of the
possible risks associated with nephrectomy to this particular
donor. There are many factors that come into play when
sharing with a recipient that a potential donor has a pre-
existing medical condition that puts him/her at greater or
uncertain long-term risk, the main one being permission
from the donor to share his/her personal medical history as it
relates to future risks. Potential kidney donors readily accept
high long-term risks, whereas potential recipients appear to
be the most averse to donor risk.61 However, it was suggested
at the Amsterdam Forum on the Care of the Live Kidney
Donor that ‘judgments should generally be made by the one
most affected by the outcome—i.e., the prospective donor
him/herself ’.3 Clearly, multicenter, long-term studies of
health outcomes for medically complex donors, such as the
patient described in this report, are essential to under-
standing which factors impart risk in a clinically important
way, and will allow both physician and potential donor to
determine acceptability of proceeding with kidney donation.
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